{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"123.5","value":"367"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"451"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"79.3","value":"87.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"446"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"58.4","value":"141"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"436"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57.6","value":"170"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"419"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40.6","value":"222"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"353"}],"units":"Participants"}],"title":"Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"87.3","value":"221"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"300"}],"units":"Participants"}],"title":"Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"221.8","value":"148"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"404"}],"units":"Participants"}],"title":"Treatment Discontinuation Visit"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"794.8","value":"8.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"}],"units":"Participants"}],"title":"Day 120 Post Last Dose of Atezolizumab"}],"denoms":[{"counts":[{"groupId":"OG000","value":"493"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.","id":"OG000","title":"Atezolizumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK-evaluable population was defined as all randomized participants who received any dose of the study treatment and who have evaluable pharmacokinetic samples. Number analyzed is the number of participants with data available for analyses at the specified timepoints.","reportingStatus":"POSTED","timeFrame":"Prior to infusion on Day 1 of Cycles 1, 2, 3, 4, 8, 16 (Cycle length = 21 days), at study discontinuation visit (up to 12 months), Day 120 post last dose of atezolizumab (up to 16 months)","title":"Minimum Serum Concentration (Cmin) at Steady-State Within a Dosing Interval of Atezolizumab","type":"SECONDARY","unitOfMeasure":"μg/ml"}